Radiant Innovation

Radiant Innovation Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Radiant Innovation (3373.TWO) as of Nov 2, 2026 is 461.36. In the previous year, Cash Conversion Cycle (CCC) was 476.02 — a change of -3.08% (lower).

Cash Conversion Cycle

461.36

YoY

-3.08%

Last updated:

Cash Conversion Cycle (CCC) of Radiant Innovation is 2025 461.36 . Cash Conversion Cycle (CCC) of Radiant Innovation was 2024 476.02 . It decreases by -3.08% lower compared to the previous year.

The Radiant Innovation Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
153.92 TWD
Jan 1, 2019
139.99 TWD
Jan 1, 2020
114.24 TWD
Jan 1, 2021
304.14 TWD
Jan 1, 2022
487.01 TWD
Jan 1, 2023
528.13 TWD
Jan 1, 2024
476.02 TWD
Jan 1, 2025
461.36 TWD
The Radiant Innovation Cash Conversion Cycle history
YEARCash Conversion CycleYoY
461.36-3.08%
476.02-9.87%
528.13+8.44%
487.01+60.12%
304.14+166.23%
114.24-18.39%
139.99-9.05%
153.92-0.39%
154.52+36.03%
113.59-3.95%
118.26-3.18%
122.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Radiant Innovation Stock analysis

What does Radiant Innovation do? Radiant Innovation Inc. generates revenue through the design, manufacture, and sale of infrared technology products. The company's main products include infrared temperature measurement instruments, ear temperature guns, frontal temperature guns, and other body temperature measurement products, alongside carbon dioxide detectors, infrared thermal imagers, and blood glucose dedicated chipsets. These products are distributed domestically and internationally across Asia, the Americas, Europe, and other regions. The primary buyers are healthcare providers, medical facilities, and electronic component distributors who require precise measurement tools and specialized components for health monitoring and diagnostics. The firm's product portfolio targets healthcare and industrial segments, with infrared thermal imagers used in building inspections and carbon dioxide detectors deployed in environmental monitoring. Blood glucose dedicated chipsets are supplied to medical device manufacturers for integration into diagnostic equipment. International distribution channels focus on regions like Asia, the Americas, and Europe, where demand for health-related measurement devices remains strong. Revenue streams are driven by direct sales to medical institutions, electronic component distributors, and industrial clients. The company's product lines serve both consumer-facing health monitoring applications and specialized industrial uses, with a strong emphasis on accuracy and reliability in temperature and gas detection technologies. Radiant Innovation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Radiant Innovation stock

Cash Conversion Cycle (CCC) of Radiant Innovation is 461.36 in 2025.

Cash Conversion Cycle (CCC) of Radiant Innovation changed from 476.02 to 461.36, representing a -3.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Radiant Innovation since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Radiant Innovation with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Radiant Innovation

All Key Metrics — Radiant Innovation